Literature DB >> 15580333

Outcome of severe adult thrombotic microangiopathies in the intensive care unit.

Frédéric Pene1, Cécile Vigneau, Marc Auburtin, Delphine Moreau, Jean-Ralph Zahar, Joël Coste, Farhad Heshmati, Jean-Paul Mira.   

Abstract

OBJECTIVE: Thrombotic microangiopathies, namely thrombotic thrombocytopenic purpura and hemolytic uremic syndrome, are uncommon microvascular occlusive diseases. Despite the dramatic improvement in the outcome by exogenous plasma supply, either through plasma infusion or through plasma exchange, patients frequently require support in the intensive care unit. In the present study, we evaluated the outcome of a large cohort of patients with severe thrombotic microangiopathies.
DESIGN: A retrospective multicenter study from January 1998 to June 2001.
SETTING: Fourteen French university hospital medical intensive care units. PATIENTS: Sixty three adult patients with severe thrombotic microangiopathies. MEASUREMENTS AND
RESULTS: Of the 63 patients, 19 had a clinical presentation of thrombotic thrombocytopenic purpura, 18 had hemolytic uremic syndrome and 26 had combined neurologic and renal failures. Infections were the main etiology associated with thrombotic microangiopathies. The mortality rate was 35%. Of the survivors, all achieved complete remission. Whereas neurologic failure assessed through the Glasgow coma scale was an independent predictor of mortality [HR=0.845 (CI 95%: 0.759-0.940), P=0.002], renal impairment did not appear to be an adverse prognostic factor. The use of plasma exchange was independently associated with survival [HR=0.269 (CI 95%: 0.104-0.691), P=0.006].
CONCLUSIONS: Thrombotic microangiopathies with severe organ dysfunctions leading to hospitalization in the intensive care unit are associated with high mortality. Neurologic impairment appears to be the main adverse prognostic factor correlated to mortality, and the study confirms the importance of plasma exchange in the treatment of high-risk patients.

Entities:  

Mesh:

Year:  2004        PMID: 15580333     DOI: 10.1007/s00134-004-2505-0

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


  33 in total

1.  Therapeutic plasma exchange: an update from the Canadian Apheresis Group.

Authors:  W F Clark; G A Rock; N Buskard; K H Shumak; P LeBlond; D Anderson; D M Sutton
Journal:  Ann Intern Med       Date:  1999-09-21       Impact factor: 25.391

2.  Plasma exchange for treatment of thrombotic thrombocytopenic purpura in critically ill patients.

Authors:  P Knöbl; C Rintelen; G Kornek; C Wiltschke; P Kalhs; I Schwarzinger; S Globits; T Staudinger; K Laczika; P Kyrle; M Frass
Journal:  Intensive Care Med       Date:  1997-01       Impact factor: 17.440

Review 3.  Thrombotic microangiopathy during pregnancy.

Authors:  K R McCrae; D B Cines
Journal:  Semin Hematol       Date:  1997-04       Impact factor: 3.851

4.  Improved survival with plasma exchange in patients with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome.

Authors:  P N Lara; T L Coe; H Zhou; L Fernando; P V Holland; T Wun
Journal:  Am J Med       Date:  1999-12       Impact factor: 4.965

5.  Serum lactate dehydrogenase and platelet count predict survival in thrombotic thrombocytopenic purpura.

Authors:  J F Patton; K R Manning; D Case; J Owen
Journal:  Am J Hematol       Date:  1994-10       Impact factor: 10.047

6.  Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group.

Authors:  G A Rock; K H Shumak; N A Buskard; V S Blanchette; J G Kelton; R C Nair; R A Spasoff
Journal:  N Engl J Med       Date:  1991-08-08       Impact factor: 91.245

7.  Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Clinical experience in 108 patients.

Authors:  W R Bell; H G Braine; P M Ness; T S Kickler
Journal:  N Engl J Med       Date:  1991-08-08       Impact factor: 91.245

8.  Specific von Willebrand factor-cleaving protease in thrombotic microangiopathies: a study of 111 cases.

Authors:  A Veyradier; B Obert; A Houllier; D Meyer; J P Girma
Journal:  Blood       Date:  2001-09-15       Impact factor: 22.113

9.  Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura.

Authors:  G G Levy; W C Nichols; E C Lian; T Foroud; J N McClintick; B M McGee; A Y Yang; D R Siemieniak; K R Stark; R Gruppo; R Sarode; S B Shurin; V Chandrasekaran; S P Stabler; H Sabio; E E Bouhassira; J D Upshaw; D Ginsburg; H M Tsai
Journal:  Nature       Date:  2001-10-04       Impact factor: 49.962

10.  Thrombotic thrombocytopenic purpura: outcome in 24 patients with renal impairment treated with plasma exchange. Canadian Apheresis Study Group.

Authors:  G Rock; K Shumak; J Kelton; V S Blanchette; N Buskard; R Nair; R Spasoff
Journal:  Transfusion       Date:  1992-10       Impact factor: 3.157

View more
  15 in total

1.  Treatment of thrombotic thrombocytopenic purpura.

Authors:  Menno van der Straaten; Sophie Jamart; Robert Wens; Philippe Gottignies; Max Dratwa; Jacques Devriendt
Journal:  Intensive Care Med       Date:  2005-02-10       Impact factor: 17.440

2.  Thrombotic microangiopathies and intensive care unit: real advances?

Authors:  François Vincent; Christophe Clec'h; Philippe Karoubi
Journal:  Intensive Care Med       Date:  2005-08-12       Impact factor: 17.440

3.  Year in review in intensive care medicine, 2005. II. Infection and sepsis, ventilator-associated pneumonia, ethics, haematology and haemostasis, ICU organisation and scoring, brain injury.

Authors:  Peter Andrews; Elie Azoulay; Massimo Antonelli; Laurent Brochard; Christian Brun-Buisson; Geoffrey Dobb; Jean-Yves Fagon; Herwig Gerlach; Johan Groeneveld; Jordi Mancebo; Philipp Metnitz; Stefano Nava; Jerome Pugin; Michael Pinsky; Peter Radermacher; Christian Richard; Robert Tasker
Journal:  Intensive Care Med       Date:  2006-02-17       Impact factor: 17.440

4.  Use of therapeutic plasma exchange in children with thrombocytopenia-associated multiple organ failure in the Turkish thrombocytopenia-associated multiple organ failure network.

Authors:  Esra Sevketoglu; Dincer Yildizdas; Ozden Ozgur Horoz; Hasan Serdar Kihtir; Tanil Kendirli; Suleyman Bayraktar; Joseph A Carcillo
Journal:  Pediatr Crit Care Med       Date:  2014-10       Impact factor: 3.624

Review 5.  Plasma exchange therapy for thrombotic microangiopathies.

Authors:  Trung C Nguyen; Yong Y Han
Journal:  Organogenesis       Date:  2011-01-01       Impact factor: 2.500

6.  Expert statement on the ICU management of patients with thrombotic thrombocytopenic purpura.

Authors:  Elie Azoulay; Philippe R Bauer; Eric Mariotte; Lene Russell; Paul Knoebl; Ignacio Martin-Loeches; Frédéric Pène; Kathryn Puxty; Pedro Povoa; Andreas Barratt-Due; Jose Garnacho-Montero; Julia Wendon; Laveena Munshi; Dominique Benoit; Michael von Bergwelt-Baildon; Marco Maggiorini; Paul Coppo; Spero Cataland; Agnès Veyradier; Andry Van de Louw
Journal:  Intensive Care Med       Date:  2019-10-07       Impact factor: 17.440

7.  Thrombotic thrombocytopenic purpura and systemic lupus erythematosus: successful management of a rare presentation.

Authors:  Pratish George; Jasmine Das; Basant Pawar; Naveen Kakkar
Journal:  Indian J Crit Care Med       Date:  2008-07

8.  Coma in thrombotic thrombocytopenic purpura.

Authors:  F J de Jong; P A W Te Boekhorst; D W J Dippel; B C Jacobs
Journal:  BMJ Case Rep       Date:  2010-11-23

Review 9.  Clinical review: specific aspects of acute renal failure in cancer patients.

Authors:  Michael Darmon; Magali Ciroldi; Guillaume Thiery; Benoît Schlemmer; Elie Azoulay
Journal:  Crit Care       Date:  2006       Impact factor: 9.097

10.  Predictive features of chronic kidney disease in atypical haemolytic uremic syndrome.

Authors:  Matthieu Jamme; Quentin Raimbourg; Dominique Chauveau; Amélie Seguin; Claire Presne; Pierre Perez; Pierre Gobert; Alain Wynckel; François Provôt; Yahsou Delmas; Christiane Mousson; Aude Servais; Laurence Vrigneaud; Agnès Veyradier; Eric Rondeau; Paul Coppo
Journal:  PLoS One       Date:  2017-05-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.